HARTFORD, Conn., Sept. 15 /PRNewswire/ -- Genomas(R), a biomedical company advancing DNA-Guided medicine, today announced the award of a 3-year Phase II Small Business Innovation Research (SBIR) Grant totaling $1.4 Million. The grant, entitled MRI DNA Biomarkers for Neuropsychiatric Disease, was awarded by the National Institute of Mental Health.
This Phase II program integrates the Genomas physiogenomics technology with the leading fMRI research of Godfrey Pearlson M.D., at Hartford Hospital’s Institute of Living, and the advanced neuro-informatics capabilities of Vincent Calhoun Ph.D., at the Mind Research Network and the University of New Mexico. MIND Institute, University of New Mexico. The research leading to this award has been published by this collaborative group in the renowned journals Human Brain Mapping and Annals of Biomedical Engineering.
SOURCE Genomas
CONTACT: Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, Inc.,
+1-860-545-4574
Web site: http://www.genomas.net/
